<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pharmacologic properties of systemic azole antifungals</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pharmacologic properties of systemic azole antifungals</h1>
<div class="graphic"><div class="figure"><div class="ttl">Pharmacologic properties of systemic azole antifungals</div><div class="cntnt"><table cellspacing="0"><colgroup span="8" width="12%"></colgroup> <tbody> <tr> <td class="subtitle1_left"> </td> <td class="subtitle1_left">Available preparations</td> <td class="subtitle1_left">Oral bioavailability</td> <td class="subtitle1_left">Metabolism and clearance</td> <td class="subtitle1_left">Enzyme/<br/> transporter inhibition*</td> <td class="subtitle1_left">Protein binding</td> <td class="subtitle1_left">Half-life in adults<br/> (hours)</td> <td class="subtitle1_left">Availability of therapeutic drug monitoring<sup>¶</sup></td> </tr> <tr> <td><strong>Fluconazole</strong></td> <td> <p>Tablet</p> <p>Oral solution</p> IV solution</td> <td>&gt;90% (unaltered by food or elevated gastric pH)</td> <td> <p>Renally as unchanged drug (80%) requiring dose adjustment in renal impairment:</p> Hepatic metabolism (11%)</td> <td>CYPs 2C19 (strong), 2C9 (moderate), 3A4 (moderate, more consistently observed with fluconazole ≥200 mg/day)</td> <td>11 to 12%</td> <td>Approximately 24; prolonged in renal impairment</td> <td>No</td> </tr> <tr> <td><strong>Isavuconazole (formulated as prodrug isavuconazonium sulfate)</strong></td> <td> <p>Capsule</p> IV solution</td> <td>98% (unaltered by food or elevated gastric pH)</td> <td>Hepatically by CYP3A4 and UGT glucuronidation</td> <td>CYP3A4 (moderate), P-gp efflux (weak to moderate)</td> <td>&gt;99%</td> <td>130</td> <td>No</td> </tr> <tr> <td><strong>Itraconazole</strong></td> <td> <p>Capsule<sup>Δ</sup></p> <p>Tablet<sup>Δ</sup></p> <p>Oral solution<sup>Δ</sup></p> <p>SUBA capsule<sup>Δ</sup></p> IV solution<sup>◊</sup> (not available in United States)</td> <td> <p>Oral capsule and tablet: approximately 55% (with food and acidic beverage); drugs that elevate gastric pH (PPI, H2 antagonists) decrease absorption of capsule</p> <p>Oral solution: approximately 75% (without food)</p> SUBA capsule: 173% (relative to traditional capsules)</td> <td>Hepatically by CYP3A4 to active metabolites</td> <td>CYP3A4 (strong), P-gp efflux</td> <td>99%</td> <td>25 to 50</td> <td> <p>Yes</p> Target trough ≥1 mcg/mL by HPLC or ≥3 mcg/mL by bioassay</td> </tr> <tr> <td><strong>Posaconazole</strong></td> <td> <p>Tablet (delayed release)</p> <p>Oral suspension</p> IV solution<sup>◊</sup></td> <td> <p>Tablet (delayed release): 54% (preferably with some food)</p> Oral suspension: variable (optimally absorbed with a high-fat meal in divided doses; however, absorption may be sufficient with any type of meal, a nutritional supplement, or an acidic beverage)</td> <td>Minimally metabolized; most drug (66%) is cleared unchanged in feces; approximately 17% undergoes hepatic UGT glucuronidation</td> <td>CYP3A4 (strong) P-gp efflux</td> <td>&gt;98%</td> <td> <p>Tablets: 26 to 31</p> <p>Suspension: approximately 35 (range 20 to 66)</p> Intravenous: approximately 27</td> <td> <p>Yes</p> <p>Prophylaxis: target trough ≥0.7 mcg/mL</p> Treatment: target trough ≥1 mcg/mL</td> </tr> <tr> <td><strong>Voriconazole</strong></td> <td> <p>Tablet</p> <p>Oral suspension</p> IV solution<sup>◊</sup></td> <td>&gt;90% (tablet and oral suspension, taken without food); absorption is decreased ≥30% when taken with food</td> <td>Hepatically by CYPs 2C19 (major)<sup>§</sup>, 2C9, and 3A4</td> <td>CYP2C19 (moderate), 3A4 (strong)</td> <td>58%</td> <td>Variable<sup>¥</sup>; dependent upon dose, serum concentration, and patient-specific characteristics (eg, CYP2C19 polymorphism)</td> <td> <p>Yes<sup>¥</sup></p> Target trough 1 to 5.5 mcg/mL</td> </tr> </tbody></table></div><div class="graphic_lgnd">Azole antifungals are subject to numerous (potentially over 1000) drug interactions, particularly with drugs that are substrates of, inhibit, or induce CYP3A drug metabolism. Some interactions can lead to undetectable serum concentrations and failure of azole antifungal therapy or dangerously toxic levels of other drugs such as immunosuppressants used in solid organ or hematopoietic cell transplantation, cardiovascular drugs, and chemotherapeutic agents. Observed effect of azole antifungal interactions may be altered by dose, timing, and route of administration. Thus, patients receiving azole antifungals should have their medication regimen analyzed for drug interactions particularly when initiating and adjusting therapy; this may be done by use of the Lexi-Interact program included with UpToDate.</div><div class="graphic_footnotes"><p>CYP: cytochrome P450 metabolism; HPLC: high-performance liquid chromatography; IV: intravenous; P-gp: P-glycoprotein efflux transporters; PPI: proton pump inhibitor; UGT: uridine 5'-diphospho-glucuronosyltransferase glucuronidation (ie, phase II [non-CYP] hepatic metabolism).</p>
<p>* The classification of azole antifungal effects on drug metabolism are based upon US Food and Drug Administration guidance. Other sources may use a different classification system resulting in some agents being classified differently. Weak inhibitor effects are not listed. Clinically significant interactions can occasionally occur due to weak inhibitors, particularly if the target drug has a narrow therapeutic margin. Refer to the <a href="https://www.uptodate.com/drug-interactions">Lexicomp drug interactions</a> program for a full list of potential interactions.</p>
<p>¶ Therapeutic targets listed are based on limited study data and should be regarded as only general guidance. Decisions about dose modification must always be made within the context of the clinical status of the patient as detailed in the UpToDate topic reviews.</p>
<p>Δ Itraconazole capsules and tablets are not bioequivalent to the oral solution and should not be interchanged on a milligram basis. Itraconazole SUBA capsules are also not bioequivalent to traditional capsules or tablets or to the oral solution.</p>
<p>◊ Intravenous solution contains a cyclodextrin vehicle that can accumulate in patients with renal impairment; refer to the topic review on the pharmacology of azoles for detailed recommendations.</p>
<p>§ CYP2C19 metabolism of voriconazole is highly polymorphic; serum concentrations may be elevated two- to fourfold in patients with low CYP2C19 expression (3 to 5% White population and African American population, 15 to 20% Asian population) relative to extensive metabolizers (ie, most patients).</p>
¥ Voriconazole exhibits nonlinear pharmacokinetics and metabolism appears to be saturable; thus, alteration of serum concentrations observed following a dose change can be disproportional to the adjustment. For example, a 50% dose increase can lead to a 150% increase in serum concentration. Refer to the UpToDate topic review on the pharmacology of azoles for details.</div><div class="graphic_reference">Data from:
<ol>
<li>US Food and Drug Administration. Clinical drug interaction studies — Cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry, January 2020. Available at: <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions" target="_blank">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions</a> (Accessed on June 5, 2020).</li>
<li>US Food &amp; Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: <a href="https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers" target="_blank">https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers</a> (Accessed on August 6, 2019).</li>
</ol></div><div id="graphicVersion">Graphic 101981 Version 18.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
